Genesis Research Confirms Full Listing on Australian Stock Exchange from 1st July
Genesis Research and Development Corporation Ltd (NZSE/ASX: GEN) today announced that it has satisfied all Australian
Stock Exchange (ASX) requirements and will transfer from a Foreign Exempt listing on ASX to a Full Listing effective 1st
July 2002. Genesis Research will continue to maintain a home exchange listing on the New Zealand Stock Exchange.
This change has been undertaken following the introduction by ASX of new requirements for maintaining a Foreign Exempt
listing.
About Genesis
Founded in 1994, Genesis is a New Zealand-based biotechnology company committed to the development of innovative
products in health and plant biotechnology from its broad genomic platform. Genesis partners with industry leaders to
develop products which have global market potential through the mining of its extensive microbe, plant and mammalian EST
databases.
Genesis’ Health Sciences Division focuses on signalling pathways involved in immune diseases and cancer and has an
extensive patent portfolio. It has three programmes in human clinical development utilising PVAC™ and AVAC™ for the
treatment of psoriasis, atopic dermatitis (eczema) and asthma. Additional pre-clinical programmes are developing YB-1,
FGFR5 and Epigen as targets for treatment of cancer and immune mediated diseases. The patented BioStore solutions for
storage of tissues and living cells are also in pre-clinical development. Collaborations are maintained with Immunex
Corporation (NASDAQ: IMNX), Corixa Corporation (NASDAQ: CRXA), SR Pharma (LSE: SPA), and Jurox Pty Ltd.
The Plant Sciences division is focusing on key cell signalling genes - novel hormones and transcription factors - to
control commercial traits including growth rates and wood fibre quality in trees, nutritional content of forage grasses,
flowering control, salt and cold tolerance. It has developed comprehensive plant EST databases including the world’s
largest EST database for commercial forestry species. It has research collaborations with ArborGen LLC, Wrightson (NZSE:
WRI), HortResearch, AgResearch and Landcare. Genesis is also undertaking significant unpartnered research programmes in
novel plant hormones. A number of patents are held including 12 steps in the production of lignin.
For more information, please visit www.genesis.co.nz